Merz Pharma has announced that it has purchased the Swiss company Anteis S.A., which specialises in the development, manufacture and commercialisation of biomedical products in the area of aesthetics.
This completes a union of two companies that have been working in strong and trustworthy partnership for many years. The acquisition strengthens Merz Aesthetics’ portfolio and reinforces its market position in the field of aesthetic medicine, while merging Anteis’ operations into one of the leading providers worldwide.
‘The acquisition of Anteis by Merz is a unique opportunity to strengthen our presence in aesthetic medicine by bringing innovative solutions to doctors and patients,’ said Philip Burchard, CEO of Merz Pharma. ‘Anteis brings substantial additions to Merz in terms of products, talent, geographic presence and manufacturing capabilities; our two portfolios complement each other perfectly.’
Since 2005, Merz Pharmaceuticals has distributed a range of dermal fillers developed by Anteis under the Belotero® brand name. With the acquisition of Anteis, Merz will further benefit from the innovative power of Anteis and its qualified and experienced employees. The acquisition is a unique opportunity to strengthen Merz’s R&D pipeline and supports the company’s strategy to establish itself as a leader in the field of aesthetics.
While the recent acquisition of Neocutis S.A., which specialises in the development of dermocosmetic pre- and post-treatments for aesthetic procedures, strengthens Merz’s position in the US market, the acquisition of Anteis enhances the company’s footprint in a whole range of markets around the world.
In less than 10 years, Anteis has become a strong global player in the area of injectable medical devices based on biopolymer transformation. Anteis has developed a number of highly innovative and highly differentiated products in the field of aesthetics (e.g. wrinkle-filling gels, resorbable implants and cutaneous rehydration gels). Their product lines Esthélis, Fortélis, Mesolis and Modélis, as well as the Jolidermis range and the Anteis Injection System, are available in over 90 countries in five continents.